UNSPSC 51101928: Cycloguanil

This classification denotes an antimalarial and folic acid antagonist with the molecular formula C11H14ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26RM326WVN, chemically known as 1-(4-chlorophenyl)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamine but generally known as cycloguanil, which bears US NIH Compound Identifier 9049. European Medicines Agency schedules Cycloguanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01526MIG.

World Health Organization schedules cycloguanil in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, CYCLOGUANIL remains the US FDA Preferred Term for this commodity. Cycloguanil bears US NLM identifiers UMLS ID C0056751 and NCI Concept Code C81015. SMILES: CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C.

UNSPSC 51101928 Cycloguanil, a Commodity code, shows minimal recent state and local procurement activity directly aligned with its nominal scope. The two opportunities tagged under this code involve antibiotic and emergency pharmaceutical products — Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone — rather than cycloguanil itself, suggesting inconsistent or error-prone coding in the state and local procurement systems that assign opportunities to this category. State and local buyers using this code appear to be health departments and county public health authorities procuring pharmaceutical inventory through piggyback cooperative agreements and competitive bidding processes, typically in multi-unit annual volumes with quarterly or on-call delivery schedules.

The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for antibiotic tablets totaling $2,999,999.11 over three years via Invitation for Bid (completed award, not an open solicitation). Seminole County, Florida issued an IFB on June 30, 2026, for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries, funded in part through FEMA, requiring electronic bid submission and inclusion of all shipping costs. Geographic activity is concentrated in Florida and Illinois, with the Illinois contract representing the larger opportunity. The code does not show robust recent solicitation volume; opportunities flagged under 51101928 are characterized by pharmaceutical product misalignment with the cycloguanil designation itself, limiting relevance to firms focused on the actual commodity the code nominally describes.